Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

InterMune Likely First To Market In IPF, But Other Firms Poised To Follow

Executive Summary

With an FDA advisory committee recommendation for approval and a May 4 PDUFA date, InterMune holds a significant lead over the rest of the field and should be first to market with a drug to treat idiopathic pulmonary fibrosis

You may also be interested in...



After Pirfenidone: Broad Competition To Bring First Therapy For Underlying Cause Of IPF To Market

In the latest in “The Pink Sheet”’s market snapshot series, InterMune continues to work on getting pirfenidone approved in the U.S., while several companies are developing next-stage therapies for IPF.

Promedior Advances Novel Fibrotic Disease Therapy In Idiopathic Pulmonary Fibrosis

The start-up is also testing the ability of its monocyte-modulating approach to prevent scarring in glaucoma surgery.

Doubling Its Bet In IPF, Gilead Buys Arresto Biosciences For $225 Million

Deal also calls for sales-based milestones, likely pegged to antibody currently in Phase I in idiopathic pulmonary fibrosis and advanced solid tumors.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS052049

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel